NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $1.99 +0.47 (+30.92%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.97 -0.02 (-1.06%) As of 05/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Imunon Stock (NASDAQ:IMNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Imunon alerts:Sign Up Key Stats Today's Range$1.60▼$2.2350-Day Range$0.40▼$2.2752-Week Range$0.37▼$3.65Volume24.07 million shsAverage Volume3.24 million shsMarket Capitalization$34.91 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingModerate Buy Company OverviewImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More… Imunon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreIMNN MarketRank™: Imunon scored higher than 37% of companies evaluated by MarketBeat, and ranked 752nd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingImunon has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 3 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($1.68) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.89% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.89% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.36 News SentimentImunon has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Imunon this week, compared to 2 articles on an average week.Search Interest11 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat Follows4 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNN Stock News HeadlinesIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 29 at 7:50 AM | seekingalpha.comImunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M MoreMay 29 at 12:57 AM | insidermonkey.com“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 30, 2025 | Brownstone Research (Ad)IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 28 at 11:32 PM | finance.yahoo.comTop Penny Stocks To Follow Now - May 26thMay 28 at 4:03 AM | americanbankingnews.comImunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News SoonMay 28 at 12:07 AM | msn.comImunon announces up to $9.75M private placement priced at-the-marketMay 27 at 7:05 PM | finance.yahoo.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 27 at 8:05 AM | globenewswire.comSee More Headlines IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.95 at the beginning of the year. Since then, IMNN shares have increased by 109.5% and is now trading at $1.99. View the best growth stocks for 2025 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) released its earnings results on Monday, May, 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. Read the conference call transcript. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO). Company Calendar Last Earnings5/12/2025Today5/29/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$17.00 Low Stock Price Target$14.00 Potential Upside/Downside+678.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-230.05% Return on Assets-128.98% Debt Debt-to-Equity RatioN/A Current Ratio2.30 Quick Ratio2.30 Sales & Book Value Annual Sales$500,000.00 Price / Sales69.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.40Miscellaneous Outstanding Shares17,542,000Free Float13,776,000Market Cap$34.91 million OptionableNot Optionable Beta1.75 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:IMNN) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.